Study of the Neural Circuits Underlying the Negative Emotional Bias of Depressive Disorders and Their Response to Ketamine (EMOKET)

This open-label, interventional trial (n=96) will investigate the neural circuits underlying negative emotional bias in depressive disorders and their response to esketamine (Spravato).

Conducted by the Centre Hospitalier St Anne, this study will examine how depressed patients attribute emotional valence to stimuli and how these biases change following esketamine treatment. Functional MRI (fMRI), pupillometry, and behavioural tasks will be used to assess emotional processing, alongside genetic and immuno-inflammatory analyses.

Participants will include adults diagnosed with major depressive disorder (MDD) or bipolar depression, with a MADRS score >20, who have been prescribed esketamine by their psychiatrist. The study aims to determine whether early improvements in emotional bias predict treatment response at four weeks. It is set to run from March 2023 to April 2026 in Paris, France.

Topic Depression Neuroscience
Compound Ketamine
Country France
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.